We have located links that may give you full text access.
Effect of Vitamin E on Diabetic Nephropathy: A Meta-Analysis.
Alternative Therapies in Health and Medicine 2024 January 2
BACKGROUND: Diabetes nephropathy has always been one of the main causes of chronic kidney disease and end-stage kidney disease (ESRD), and diabetes nephropathy accounts for about 40% of ESRD cases. Vitamin E can effectively reduce urinary microalbumin, urinary albumin excretion rate and serum nitric oxide level in patients with type 2 diabetes nephropathy.
METHODS: The computer retrieves four databases to obtain controlled trials on the effects of vitamin E in patients with diabetic nephropathy. After a rigorous literature quality evaluation, data analysis was performed using Stata software. Study Design Type Published controlled trials on the effects of vitamin E in patients with diabetic nephropathy. However, the animal trials were excluded. The intervention group received vitamin E in the treatment of patients with diabetic nephropathy, and the control group received a placebo in the treatment of patients with diabetic nephropathy. Outcome indicators patients with diabetic nephropathy; According to research, the assessment tools for the effects of vitamin E in patients with diabetic nephropathy are: (1) HbA1c (Glycated hemoglobin,%); (2) EGFR (mL/min 1.73 m2); (3) Serum creatinine (μmol/L); (4) Urea (mmol/L); (5) Systolic BP (mmHg); (6) Diastolic BP (mmHg).
RESULTS: 5 studies were ultimately included in this meta-analysis. 5 studies reported the glycosylated hemoglobin (HbA1c) of the test group and the control group, which was significantly lower (SMD: -0.17; 95% Cl: -0.26,-0.07; P < .01) than the control group. Meta-analysis showed that the Serum creatinine of the test group was also significantly lower (SMD: -11.20; 95% Cl: -12.89,-9.51; P < .01) than the control group. EGFR of the test group had no significant statistical significance (SMD: -0.90; 95% Cl: -13.30,11.49; P = .886) than the control group. Meta-analysis showed that the urea of the test group had no significant statistical significance(SMD: -0.57; 95% Cl: -1.58,0.45; P = .275). The systolic BP (SMD: -3.95; 95% Cl: -9.79,1.88; P = .184) and Diastolic BP (SMD: 0.26; 95% Cl: -0.75,1.27; P = .617) are also consistent with the group.
CONCLUSION: The results of this study suggest that vitamin E may be effective on in patients with diabetic nephropathy, as evidenced by HbA1c and Serum creatinine, and the above conclusions need to be verified by more high-quality studies.
METHODS: The computer retrieves four databases to obtain controlled trials on the effects of vitamin E in patients with diabetic nephropathy. After a rigorous literature quality evaluation, data analysis was performed using Stata software. Study Design Type Published controlled trials on the effects of vitamin E in patients with diabetic nephropathy. However, the animal trials were excluded. The intervention group received vitamin E in the treatment of patients with diabetic nephropathy, and the control group received a placebo in the treatment of patients with diabetic nephropathy. Outcome indicators patients with diabetic nephropathy; According to research, the assessment tools for the effects of vitamin E in patients with diabetic nephropathy are: (1) HbA1c (Glycated hemoglobin,%); (2) EGFR (mL/min 1.73 m2); (3) Serum creatinine (μmol/L); (4) Urea (mmol/L); (5) Systolic BP (mmHg); (6) Diastolic BP (mmHg).
RESULTS: 5 studies were ultimately included in this meta-analysis. 5 studies reported the glycosylated hemoglobin (HbA1c) of the test group and the control group, which was significantly lower (SMD: -0.17; 95% Cl: -0.26,-0.07; P < .01) than the control group. Meta-analysis showed that the Serum creatinine of the test group was also significantly lower (SMD: -11.20; 95% Cl: -12.89,-9.51; P < .01) than the control group. EGFR of the test group had no significant statistical significance (SMD: -0.90; 95% Cl: -13.30,11.49; P = .886) than the control group. Meta-analysis showed that the urea of the test group had no significant statistical significance(SMD: -0.57; 95% Cl: -1.58,0.45; P = .275). The systolic BP (SMD: -3.95; 95% Cl: -9.79,1.88; P = .184) and Diastolic BP (SMD: 0.26; 95% Cl: -0.75,1.27; P = .617) are also consistent with the group.
CONCLUSION: The results of this study suggest that vitamin E may be effective on in patients with diabetic nephropathy, as evidenced by HbA1c and Serum creatinine, and the above conclusions need to be verified by more high-quality studies.
Full text links
Related Resources
Trending Papers
Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows.Endocrine Reviews 2024 April 28
The Tricuspid Valve: A Review of Pathology, Imaging, and Current Treatment Options: A Scientific Statement From the American Heart Association.Circulation 2024 April 26
British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults.Gut 2024 April 17
Interstitial Lung Disease: A Review.JAMA 2024 April 23
Ventilator Waveforms May Give Clues to Expiratory Muscle Activity.American Journal of Respiratory and Critical Care Medicine 2024 April 25
Systemic lupus erythematosus.Lancet 2024 April 18
Acute Kidney Injury and Electrolyte Imbalances Caused by Dapagliflozin Short-Term Use.Pharmaceuticals 2024 March 27
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app